
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-302
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : LaNova Medicines
Deal Size : $951.0 million
Deal Type : Acquisition
Sino Biopharmaceutical to Acquire LaNova Medicines for up to $951 million
Details : Upon completion of the acquisition, LaNova will become a wholly owned subsidiary of Sino. Its lead product, LM-302, is being evaluated for the treatment of CLDN18.2-positive gastric cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : LM-302
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : LaNova Medicines
Deal Size : $951.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : LaNova Medicines
Deal Size : $42.0 million
Deal Type : Series C Financing
LaNova Initiates Phase 1 for LM-299 Anti-PD-1/VEGF Antibody and $42M Financing
Details : The financing is intended to support the clinical development of LM-302, an anti-CLDN 18.2 ADC, which is currently in late-stage clinical trials in China for the treatment of gastric cancers.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 18, 2024
Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : LaNova Medicines
Deal Size : $42.0 million
Deal Type : Series C Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lanifibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Recipient : Inventiva Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Lanifibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Recipient : Inventiva Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lanifibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Recipient : Inventiva Pharma
Deal Size : $307.0 million
Deal Type : Licensing Agreement
Details : Lanifibranor (IVA337), is an orally-available small molecule with breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) following a positive Phase IIb trial in patients with non-alcoholic steatohepatitis (NASH).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $12.0 million
September 21, 2022
Lead Product(s) : Lanifibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Recipient : Inventiva Pharma
Deal Size : $307.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CFI-400945,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Treadwell Therapeutics
Deal Size : $91.0 million
Deal Type : Series B Financing
Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing
Details : Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform, as well as general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 18, 2021
Lead Product(s) : CFI-400945,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Treadwell Therapeutics
Deal Size : $91.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Penpulimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
Details : Penpulimab is currently the only new PD-1 monoclonal antibody that applies IgG1 subtype and is modified by Fc segment, which has a lower antigen binding dissociation rate and a unique binding epitope as demonstrated by analysis on crystal structure.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 05, 2021
Lead Product(s) : Penpulimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Sinovac Biotech
Deal Size : $500.0 million
Deal Type : Funding
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
Details : The investment deal comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.
Product Name : CoronaVac
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 07, 2020
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Sinovac Biotech
Deal Size : $500.0 million
Deal Type : Funding
